The impact of SLCO1B1 genetic polymorphisms on neonatal hyperbilirubinemia: a systematic review with meta-analysis  by Liu, Jiebo et al.
JR
T
h
J
a
b
R
A
b
0
h Pediatr (Rio J). 2013;89(5):434--443
www.jped.com.br
EVIEW ARTICLE
he  impact  of SLCO1B1  genetic  polymorphisms  on neonatal
yperbilirubinemia: a systematic  review  with meta-analysis
iebo Liua,∗, Jun Longb, Shaofang Zhangb, Xiaoyan Fangb, Yuyuan Luob
PhD.  Department  of  Pediatrics,  The  Fifth  People’s  Hospital  of  Shenzhen,  Shenzhen,  China
MD.  Department  of  Pediatrics,  The  Fifth  People’s  Hospital  of  Shenzhen,  Shenzhen,  China
eceived  14  November  2012;  accepted  30  January  2013
vailable  online  11  July  2013
KEYWORDS
Genetic
polymorphisms;
Neonatal
hyperbilirubinemia;
Organic  anion
transport  polypeptide
C;
Meta-analysis
Abstract
Objective:  To  determine  whether  three  variants  (388  G>A,  521  T>C,  and  463  C>A)  of  the  solute
carrier organic  anion  transporter  family  member  1B1  (SLCO1B1)  are  associated  with  neonatal
hyperbilirubinemia.
Data  source:  The  China  National  Knowledge  Infrastructure  and  MEDLINE  databases  were
searched. The  systematic  review  with  meta-analysis  included  genetic  studies  which  assessed
the  association  between  neonatal  hyperbilirubinemia  and  388  G>A,  521  T>C,  and  463  C>A  vari-
ants  of  SLCO1B1  between  January  of  1980  and  December  of  2012.  Data  selection  and  extraction
were  performed  independently  by  two  reviewers.
Summary  of  the  ﬁndings:  Ten  articles  were  included  in  the  study.  The  results  revealed  that
SLCO1B1 388  G>A  is  associated  with  an  increased  risk  of  neonatal  hyperbilirubinemia  (OR,  1.39;
95%  CI,  1.07--1.82)  in  Chinese  neonates,  but  not  in  white,  Thai,  Latin  American,  or  Malaysian
neonates.  The  SLCO1B1  521  T>C  mutation  showed  a  low  risk  of  neonatal  hyperbilirubinemia  in
Chinese  neonates,  while  no  signiﬁcant  associations  were  found  in  Brazilian,  white,  Asian,  Thai,
and  Malaysian  neonates.  There  were  no  signiﬁcant  differences  in  SLCO1B1  463  C>A  between
the  hyperbilirubinemia  and  the  control  group.
Conclusion:  This  study  demonstrated  that  the  388  G>A  mutation  of  the  SLCO1B1  gene  is  a
risk factor  for  developing  neonatal  hyperbilirubinemia  in  Chinese  neonates,  but  not  in  white,
Thai,  Brazilian,  or  Malaysian  populations;  the  SLCO1B1  521  T>C  mutation  provides  protection  for
neonatal  hyperbilirubinemia  in  Chinese  neonates,  but  not  in  white,  Thai,  Brazilian,  or  Malaysian
populations.
©  2013  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  
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Impacto  dos  polimorﬁsmos  genéticos  SLCO1B1  sobre  a  hiperbilirrubinemia  neonatal:
revisão  sistemática  com  metanálise
Resumo
Objetivo:  Determinar  se  três  variantes  (388  G>A,  521  T>C,  463  C>A)  do  membro  1B1  da  família
de transportadores  de  ânions  orgânicos  portadores  de  solutos  (SLCO1B1)  se  associam  à  hiper-
bilirrubinemia  neonatal.
Fonte de  dados: Foi  realizada  busca  na  Infraestrutura  do  Conhecimento  Nacional  da  China  e
em MEDLINE.  A  revisão  sistemática  com  metanálise  incluiu  estudos  genéticos  que  avaliaram  a
associac¸ão  entre  hiperbilirrubinemia  neonatal  e  as  variantes  388  G>A,  521  T>C,  463  C>A  de
SLCO1B1  entre  janeiro  de  1980  e  dezembro  de  2012.  Foi  realizada  selec¸ão  e  extrac¸ão  de  dados
por  dois  analistas,  de  forma  independente.
Sumário  dos  achados:  Foram  incluídos  dez  artigos  no  estudo.  Os  resultados  revelaram  que
SLCO1B1 388  G>A  se  associa  a  um  aumento  do  risco  de  hiperbilirrubinemia  neonatal  (OR<  1,39;
IC  95%:  1,07  a  1,82)  em  recém-nascidos  chineses,  mas  não  em  recém-nascidos  caucasianos,
tailandeses,  latino-americanos  ou  malaios.  A  mutac¸ão  SLCO1B1  521  T>C  mostrou  baixo  risco  de
hiperbilirrubinemia  neonatal  em  recém-nascido  chineses,  e  não  foram  encontradas  associac¸ões
importantes  no  Brasil  nem  em  recém-nascidos  caucasianos,  asiáticos,  tailandeses  e  malaios.
Não  houve  diferenc¸as  signiﬁcativas  da  SLCO1B1  463  C>A  entre  o  grupo  com  hiperbilirrubinemia
e o  grupo  controle.
Conclusão:  O  estudo  mostrou  que  a  mutac¸ão  388  G>A  do  gene  SLCO1B1  é  fator  de  risco  para
desenvolver hiperbilirrubinemia  neonatal  em  recém-nascidos  chineses,  mas  não  em  populac¸ões
caucasianas,  tailandesas,  brasileiras  ou  malaias;  a  mutac¸ão  SLCO1B1  521  T>C  fornece  protec¸ão
de hiperbilirrubinemia  neonatal  em  recém-nascidos  chineses,  mas  não  nas  populac¸ões  cau-
casianas,  tailandesas,  brasileiras  ou  malaias.
©  2013  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  
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Este é um artigo Open Access sob a licença de CC BY-NC-NDIntroduction
Hyperbilirubinemia  is  the  most  common  clinical  condition
in newborns.  Between  8%  and  11%  of  neonates  develop  sig-
niﬁcant hyperbilirubinemia,  deﬁned  as  total  serum  bilirubin
(TSB) above  the  95th  percentile  for  age  (high-risk  zone)  dur-
ing the  ﬁrst  week  of  life.1 The  levels  of  TSB  rise  to  the
high-risk zone,  leading  to  long-term  consequences,  including
bilirubin-induced encephalopathy  and  kernicterus.2 Despite
the advent  of  phototherapy  and  exchange  transfusion,  ker-
nicterus continues  to  be  reported  worldwide,  especially  in
developing countries.3
Therefore,  the  identiﬁcation  of  infants  at  risk  of  devel-
oping neonatal  hyperbilirubinemia  has  become  particularly
important.4 There  are  many  factors  that  could  account  for
the development  of  neonatal  hyperbilirubinemia,  including
ABO or  Rh  incompatibilities,  deﬁciency  of  glucose-6-
phosphate dehydrogenase  (G6PD)  and  pyruvate  kinase,
hereditary spherocytosis,  defective  hemoglobin  synthesis,
hypothyroidism, breast  milk  jaundice,  and  cephalohe-
matoma, among  others.5
Several  clinical  genetic  disorders  inﬂuence  bilirubin  phys-
iology. The  UDP-glycosyltransferase  1  family,  polypeptide
A1 (UGT1A1),  and  solute  carrier  organic  anion  transporter
family enzymes  organic  anion  transporter  polypeptide  2
(OATP2) are  responsible  for  glucuronidation  and  cellular
uptake of  bilirubin,  respectively,  and  play  an  important
role in  regulating  the  bilirubin  levels.6 OATP2  is  located
on the  basolateral  (sinusoidal)  membrane  of  human  hep-
atocytes, and  is  encoded  by  the  gene  of  the  solute
S
T
earrier  organic  anion  transporter  family  member  1B1
SLCO1B1).
Recent studies  have  suggested  that  the  variations  388
>A, 521  T>C,  and  463  C>A  of  the  SLCO1B1  gene  may  pre-
ispose subjects  to  neonatal  hyperbilirubinemia  by  limiting
epatic bilirubin  uptake.7 They  vary  in  different  popula-
ions, with  a  high  prevalence  of  the  388  G>A  (73.4%)  and
21 T>C  (14.0%)  variants  occurring  in  Chinese  subjects.8 A
6% prevalence  of  the  463  C>A  variant  has  been  reported  in
uropeans and  Americans.9 Neonatal  hyperbilirubinemia  is
nown to  occur  more  frequently  and  to  be  more  severe
n Asians  than  in  whites.10 The  authors  hypothesized  that
LCO1B1 mutation  may  be  one  of  the  risk  factors  for  neona-
al hyperbilirubinemia,  which  possibly  accounts  for  the  vari-
bility in  prevalence  rates  among  different  ethnic  groups.
he role  of  SLCO1B1  gene  in  neonatal  hyperbilirubinemia
s still  controversial.  Thus,  the  objective  of  this  systematic
eview with  meta-analysis  was  to  assess  the  impact  of  the
hree variants  (388  G>A,  521  T>C,  463  C>A)  of  SLCO1B1  on
yperbilirubinemia in  neonates  of  different  ethnicities.
ethods
his  systematic  review  with  meta-analysis  was  based  on  a
ethod recommended  by  the  Human  Genome  Epidemiology
etwork (http://www.cdc.gov/genomics/hugenet).election  of  studies
he  electronic  databases  of  the  China  National  Knowl-
dge Infrastructure  and  MEDLINE  were  searched  for  all
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ase-control  or  cohort  studies  that  evaluated  SLCO1B1  in
ssociation with  neonatal  hyperbilirubinemia  between  Jan-
ary  of  1980  and  December  of  2012,  using  the  following
earch strategy:  (Hyperbilirubinemia,  Neonatal  OR  (Biliru-
in AND  Infant,  Newborn)  OR  Jaundice,  Neonatal)  AND
Organic Anion  Transporters  OR  Polymorphism,  Restriction
ragment Length  OR  SLCO1B1  protein,  Organic  Anion  Trans-
ort Polypeptide  C  OR  Genetic  Predisposition  to  Disease  OR
olymorphism).
The MEDLINE  database  was  searched  using  the  following
earch strategy:  (Hyperbilirubinemia,  Neonatal  OR  (Bilirubin
ND Infant,  Newborn)  OR  Jaundice,  Neonatal)  AND  (Organic
nion Transporters  OR  Polymorphism,  Restriction  Fragment
ength OR  SLCO1B1  protein,  human  OR  DNA  Mutational
nalysis OR  Gene  Frequency  OR  Genotype  OR  Mutation  OR
rganic Anion  Transport  Polypeptide  C  OR  Genetic  Predis-
osition to  Disease  OR  Polymorphism,  Genetic  OR  DNA  OR
olymorphism, Single  Nucleotide).  No  language  restrictions
ere applied.
nclusion  and  exclusion  criteria
olymorphisms  related  to  neonatal  hyperbilirubinemia  were
ivided  into  three  groups  according  to  the  three  variants
388 G>A,  521  T>C,  and  463  C>A)  of  SLCO1B1.  Case-control,
ohort, and  family-based  studies  presenting  original  data
n associations  between  the  genetic  polymorphisms  and
eonatal hyperbilirubinemia  were  eligible  for  inclusion,  pro-
ided that  (i)  the  cases  of  neonatal  hyperbilirubinemia  were
ncluded  according  to  the  diagnostic  criteria  utilized  in  vari-
us countries;  (ii)  the  control  group  consisted  of  comparable
nfants without  a  history  of  hyperbilirubinemia;  (iii)  the
nrollment of  participants  was  made  based  on  prior  knowl-
dge of  genotype,  and  genotyping;  (iv)  the  study  reported
he ethnic  ancestry  of  participants;  and  (v)  the  reported
enotype distributions  were  in  Hardy-Weinberg  equilibrium.
ardy-Weinberg equilibrium  was  performed  by  chi-squared
nalysis. Exclusion  criteria  included  review  articles  as  well
s articles  that  studied  populations  aged  up  to  28  days.
ata  extraction
wo  investigators  (Long  J  and  Zhang  SF)  extracted  data
ndependently. When  conﬂicting  evaluations  occurred,  an
greement was  reached  after  a  discussion.  Brieﬂy,  for  all
tudies, the  following  data  were  extracted  from  the  original
ublications: ﬁrst  author  and  year  of  publication;  genes  and
elevant polymorphisms;  neonatal  hyperbilirubinemia  def-
nition; study  population;  number  of  genotyped  cases  and
ontrols; frequencies  of  genotype;  and  SLCO1B1  gene  poly-
orphism genotyping  information.
tatistical  analysis
tata  software  (version  9.0;  Stata  Corp.  LP  -  College  Station,
X, USA)  was  used  to  pool  data  from  case--control  or
ohort studies.  These  studies  mainly  provided  three  geno-
ypes, and  these  genotype  groups  were  assessed  using
llelic comparisons  and  mutant  comparisons  (heterozygous
nd homozygous  mutant  type  vs.  homozygous  wild  type).
o
E
i
nLiu  J  et  al.
esults  were  given  as  odds  ratios  (OR)  with  95%  conﬁdence
ntervals (CI),  and  a p-value  <  0.05  was  considered  to  be
tatistically signiﬁcant.  The  heterogeneity  assumption  was
hecked using  an  I2 statistic.  An  I2 value  of  >  50%  signiﬁed
‘substantial heterogeneity’’,  and  a random  effects  model
as used.  An  I2 value  of  ≤  50%  showed  the  absence  of  hetero-
eneity and  defaulted  to  the  ﬁxed  effects  model  approach.
unnel plots  and  Egger’s  linear  regression  test  were  used
o identify  potential  publication  bias,  and  p  <  0.05  was
onsidered indicative  of  statistically  signiﬁcant  publication
ias.
esults
he  literature  search  identiﬁed  546  articles  on  the
ssociation between  genetic  polymorphisms  and  neona-
al hyperbilirubinemia.  Of  these,  536  were  subsequently
xcluded after  screening  of  abstracts  or  full  texts.  Ulti-
ately, 10  articles  were  assessed  as  useful  for  the  systematic
eview with  meta-analysis,11--20 and  nine  studies  were
ncluded in  the  meta-analysis.11--19 The  ﬂow  diagram  of
tudy identiﬁcation  is  shown  in  Fig.  1.  These  studies  were
onducted on  six  countries  (China,  Malaysia,  Thailand,  the
nited States,  Brazil,  and  Turkey).  They  included  1,164
ases of  neonatal  hyperbilirubinemia  and  1,416  controls.
he characteristics  of  the  included  studies  are  summarized
n Table  1.
In one  study  included  in  the  systematic  review,  there
ere no  statistically  signiﬁcant  differences  in  the  risk  of
eonatal hyperbilirubinemia  for  the  388  G>A  and  521  T>C
ariants of  SLCO1B1.11 Nine  studies  were  included  in  the
eta-analysis, which  assessed  the  association  between  the
LCO1B1 388  G>A  mutation  and  neonatal  hyperbilirubinemia
Table 2).12--20
Results  of  the  meta-analysis  indicated  that  there  was
o statistically  signiﬁcant  difference  in  the  risk  of  neonatal
yperbilirubinemia between  SLCO1B1  388  G>A  allele  carri-
rs (A/A+G/A)  and  G/G  allele  carriers  (OR,  1.07;  95%  CI:
.90--1.28) (Fig.  2).  A  signiﬁcant  inter-study  heterogeneity
as observed  (p  =  0.00).  Egger’s  test  provided  no  evidence
or funnel  plot  asymmetry  in  the  comparison  of  the  SLCO1B1
88 G>A  mutation  and  neonatal  hyperbilirubinemia  (t  =  2.12,
 =  0.07).
Additionally, in  the  subgroup  analyses  based  on  ethnic-
ty, no  signiﬁcant  associations  were  found  in  white  (OR,
.01; 95%  CI:  0.69--1.49),  Asian,  Thai,  Latin  American,
r Malaysian  populations  (Table  3).  However,  signiﬁcantly
levated risks  were  found  in  the  SLCO1B1  388  G>A  vari-
nt genotypes  in  Chinese  neonates  (OR,  1.39;  95%  CI:
.07--1.82). A  signiﬁcant  inter-study  heterogeneity  was  also
bserved in  subgroup  analysis  of  Asian  populations  (p  =  0.02).
Meta-analysis  comparing  the  A  allele  to  the  G  allele  in  the
LCO1B1 388  G>A  mutation  also  showed  an  increased  risk  of
eonatal hyperbilirubinemia  (OR,  1.32;  95%  CI:  1.06--1.64)  in
hinese neonates,  but  not  in  white,  Thai,  Latin  American,  or
alaysian populations  (Fig.  3  and  Table  3).  Signiﬁcant  inter-
tudy heterogeneity  was  also  observed  in  subgroup  analyses
f Asian  and  Chinese  neonates,  but  not  in  white  populations.
gger’s test  provided  no  evidence  for  funnel  plot  asymmetry
n the  comparison  of  the  SLCO1B1  388  G>A  mutation  and
eonatal hyperbilirubinemia  (t  =  2.29,  p  =  0.06).
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Table  1  Characteristics  of  included  studies.
Reference  Country  Cases  (n)  Control  (n)  Gestational  ages,
cases/controls
(mean±SD,  weeks)
Birth weights,
cases/controls
(mean±SD,  g)
Characteristics  of  included
cases
Characteristics  of
controls
Chang  et  al.11 Taiwan 59 193  38.7±1.0/38.9±1.1 3,158±406/3,221±458 Bilirubin  level  >  the  85th
percentile (≥  15mg/dL)  on  the
bilirubin  nomogram  in  the
latter portion  of  the  third  day
Healthy  controls  with
no hyperbilirubinemia
Zhang  et  al.12 China  220  200  38.7±5.2/38.5±5.5 2,780±260/2,850±  290 Neonates with  STB  >  154  mM  at
24  h,  205  mM  at  48  h,  257  mM
at 72  h,  291  mM  for  more  than
72 h
Healthy  controls  with
no hyperbilirubinemia
Tian  et  al.13 China  96  101  38.9±1.5/38.6±1.3 3,250±417/3,283±376 Neonates  with  STB  ≥  257  M  in
the ﬁrst  7  days,  unconjugated
bilirubin
Healthy  neonates
with STB  <  180  M
Jiang  et  al.14 China  163  63  Not  stated Not stated Neonates  with  STB  >  220.6  mM
in  the  ﬁrst  14  days
Healthy  controls  with
no hyperbilirubinemia
Huang  et  al.15 Taiwan 58 75  Not  stated Not stated Neonates  with  a  peak  STB  ≥
342  M  in  the  ﬁrst  10  days,
unconjugated  bilirubin
Healthy  neonates
with STB  <  256.5  M
Wong  et  al.16 Malaysia  65  110  38.3±1.4/38.7±1.1  3,043±377/3,051±470  Neonates  with  STB  ≥  342  M
within the  ﬁrst  10  days
Healthy  controls  with
STB <  256.5  M
Prachukthum  et  al.17 Thailand  91  86  38.48±1.09/38.62±1.09  3,147.69±425.30/
3,152.91±374.96
Neonates  with  STB  above  the
95th  percentile  as  deﬁned  by
the  Bhutani  nomogram
Neonates  with  STB
below the  40th
percentile  as  deﬁned
by the  Bhutani
nomogram
Watchko  et  al.18 America  153  299  39  (37-40)/39  (37-40)  3,315
(2,777-4,036)/3,374
(2,815-3,898)
Neonates  with  STB  above  the
95th  percentile  as  deﬁned  by
the  Bhutani  nomogram
Neonates  with  STB
below the  40th
percentile  as  deﬁned
by the  Bhutani
nomogram
Büyükkale  et  al.19 Turkey 102 53  38±1.7(n  =  65),
38±1.5(n =
37)/38±1.6(n  =  53)
3,156±569 (n  =  65),
3,233±496 (n  =  37)/
3,248±412 (n  =  53)
Neonates with  STB  above  the
95th  percentile  as  deﬁned  by
the  Bhutani  nomogram
Neonates  with  STB
below the  40th
percentile  as  deﬁned
by the  Bhutani
nomogram
Alencastro  de
Azevedo et  al.20
Brazil  167  247  38.1±1.8/39.5±1.4 3,099±460/3,218±  460 Infants with  TSB  that  had
indications for  phototherapy  in
accordance  with  the  guidelines
of the  AAP
Infants  did  not  show
signs for
phototherapy
according  to  visual  or
laboratory evaluation
AAP, American Academy of Pediatrics; SD, standard deviation; STB, serum total bilirubin; TSB, total serum bilirubin.
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Full-text articles assessed for eligibility
(n = 21)
Studies on SLCO1B1 polymorphisms and
neonatal hyperbilirubinemia (n = 12)
Studies were assessed to be useful for systematic
review with meta-analysis (n = 10), nine studies
included in the meta-analysis.
Studies excluded for study population aged up to 28
days (n = 2)
Studies were excluded for the following reasons:
- Review papers (n = 125)
- Did not address SLCO1B1 polymorphisms in 
  neonatal hyperbilirubinemia (n = 321)
- Not case-control, cohort, and family-based studies 
  on neonatal hyperbilirubinemia (n = 79)
Studies on genetic polymorphisms and neonatal
hyperbilirubinemia were identified (n = 546)
Studies were excluded for reporting the relationship
between polymorphisms and G-6-PD deficiency,
Gilbert syndrome, or Crigler-Najjar syndrome (n = 9)
Figure  1  Flow  diagram  of  study  identiﬁcation.  CI,  conﬁdence  interval;  SLCO1B1,  solute  carrier  organic  anion  transporter  family
member  1B1.
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allele).  CI,  conﬁdence  interval;  SLCO1B1,  solute  carrier  organic
Five  case--control  studies  from  three  countries,  which
includes our  study,  with  637  hyperbilirubinemic  case
subjects and  918  control  subjects,  were  included  in  the
meta-analysis of  the  association  between  the  SLCO1B1
521 T>C  mutation  and  neonatal  hyperbilirubinemia
(Table 4).12,15,16,19,20 Results  of  the  meta-analysis  indicated
that there  was  no  statistically  signiﬁcant  difference  in
the risk  of  neonatal  hyperbilirubinemia  between  SLCO1B1
521 T>C  allele  carriers  (C/C+C/T)  and  T/T  allele  carriers
(Fig. 4);  the  same  was  observed  when  comparing  the  T  allele
to the  C  allele  in  the  SLCO1B1  521  T>C  mutation  (Fig.  5).  In
addition, in  the  subgroup  analyses  based  on  ethnicity,  low
risk of  neonatal  hyperbilirubinemia  was  found  in  Chinese
neonates, and  no  signiﬁcant  associations  between  SLCO1B1
521 T>C  allele  carriers  (C/C+C/T)  and  T/T  allele  carriers
S
m
a
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Table  2  Genotypic  frequencies  of  SLCO1B1  388  G>A  in  neonatal  
Study  Country  of  origin  
G/G  
Asian  studies
Zhang  et  al.12 China  127  
Tian  et  al.13 China  56  
Jiang  et  al.14 China  95  
Huang  et  al.15 Taiwan  31  
Wong  et  al.16 Malaysia  38  
Prachukthum  et  al.17 Thailand  59  
White  studies
Watchko  et  al.18 America  118  
Büyükkale  et  al.19 Turkey  30  
Latin  American  studies
Alencastro de  Azevedo  et  al.20 Brazil  42  
SLCO1B1, solute carrier organic anion transporter family member 1B1.ubinemic  group  and  control  group  (comparison  of  A  allele  vs.  G
n  transporter  family  member  1B1.
ere  found  in  Brazilian,  white,  Asian,  Thai,  and  Malaysian
eonates; the  same  was  observed  when  comparing  the  T
llele to  the  C  allele  in  the  SLCO1B1  521  T>C  mutation
Table 5).  Egger’s  test  provided  no  evidence  for  funnel  plot
symmetry in  comparisons  of  SLCO1B1  521  T>C  mutations
nd neonatal  hyperbilirubinemia  (comparison  of  C/C+C/T
s. T/T:  t  =  0.25,  p  =  0.82;  comparison  of  T  allele  vs.  C
llele: t  =  0.40,  p  =  0.71).
Three  case--control  studies  from  three  countries,  with
86 hyperbilirubinemic  cases  and  456  controls,  were
ncluded in  the  meta-analysis  of  the  association  between  the
LCO1B1 463  C>A  mutation  and  neonatal  hyperbilirubine-
ia (Table  6).15,17,18 No  carriage  of  the  C  to  A  substitution
t nucleotide  463  was  detected  in  two  studies,  and  only
ne study,18 which  involved  American  subjects,  showed  31
hyperbilirubinemic  cases  and  in  controls.
Cases  (n)  Control  (n)
A/G  A/A  G/G  A/G  A/A
75  18  102  77  21
29  11  75  21  5
52  16  53  8  2
20  7  53  16  6
19  8  55  47  8
28  4  47  36  3
33  2  228  65  5
56  16  17  24  12
78  37  58  123  56
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Table  3  Subgroup  analysis  of  SLCO1B1  388  G>A  in  neonatal  hyperbilirubinemic  cases  and  in  controls.
Polymorphism  No.  of  studies  (n)  No.  of  cases/controls  (n)  Odds  ratio  (95%  CI)  p  Heterogeneity
I2 (%)  p
A/A+G/A  vs.G/G
Asia 6  693/635  1.14  (0.91-1.43)  0.24  80.9  0.00
China 4  537/439  1.39  (1.07-1.82)  0.02  84.4  0.00
Thailand 1  91/86  0.65  (0.36-1.20)  >  0.05  -  -
Malaysia 1  65/110  0.71  (0.38-1.32)  >  0.05  -  -
White 2  255/352  1.01  (0.69-1.49)  0.95  0.0  0.71
Latin America  1  157/237  0.89  (0.56-1.41)  >  0.05  -  -
Total 9  1,105/1223  1.07  (0.90-1.28)  0.45  70.5  0.00
A allele  vs.G  allele
Asia 6  693/635  1.17  (0.97-1.40)  0.10  81.0  0.00
China 4  537/439  1.32  (1.06-1.64)  0.01  86.5  0.00
Thailand 1  91/86  0.76  (0.46-1.26)  >  0.05  -  -
Malaysia 1  65/110  0.92  (0.57-1.49)  >  0.05  -  -
White 2  255/352  0.94  (0.69-1.29)  0.69  0.0  0.89
Latin America  1  157/237  0.95  (0.72-1.27)  >  0.05  -  -
Total 9  1,105/1,223  1.07  (0.93-1.22)  0.36  71.4  0.00
CI, conﬁdence interval; SLCO1B1, solute carrier organic anion transporter family member 1B1.
Table  4  Genotypic  frequencies  of  SLCO1B1  521  T>C  in  neonatal  hyperbilirubinemic  cases  and  in  controls.
Study  Country  of  origin  Cases  (n)  Controls  (n)
T/T  T/C  C/C  T/T  T/C  C/C
Zhang  et  al.12 China  185  34  1  147  50  3
Huang  et  al.15 Taiwan  31  9  2  53  19  1
Wong  et  al.16 Malaysia  47  18  0  81  29  0
Watchko  et  al.19 America  58  69  26  135  117  46
Alencastro  de  Azevedo  et  al.20 Brazil  122  34  1  179  55  3
CI, conﬁdence interval; SLCO1B1, solute carrier organic anion transporter family member 1B1.
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Figure  5  Meta-analysis  of  SLCO1B1  521  T>C  in  neonatal  hyperbilirubinemic  group  and  control  group  (comparison  of  T  allele  vs.  C
allele).  CI,  conﬁdence  interval;  SLCO1B1,  solute  carrier  organic  anion  transporter  family  member  1B1.
Table  5  Subgroup  analysis  of  SLCO1B1  521  T>C  in  neonatal  hyperbilirubinemic  cases  and  in  controls.
Polymorphism  No.  of  studies  (n)  No.  of  cases/controls  (n)  Odds  ratio  (95%  CI)  p  Heterogeneity
I2 (%)  p
C/C+C/T  vs.  T/T
Asia 3  327/383  0.70  (0.49-1.00)  0.05  39.4  0.19
China 2  262/273  0.60  (0.40-0.92)  0.02  26.0  0.25
Malaysia  1  65/110  1.07  (0.54-2.13)  >  0.05  - -
White 1  153/299  1.36(0.91-2.02)  >  0.05  - -
Latin America  1  157/237  0.89(0.55-1.43)  >  0.05  - -
Total 5  637/918  0.93  (0.74-1.17)  0.52  56.2  0.06
C allele  vs.  T  allele
Asia 3  327/383  0.74  (0.53-1.03)  0.07  50.4  0.13
China 2  262/273  0.65  (0.45-0.96)  0.03  58.3  0.12
Malaysia  1  65/110  1.06  (0.56-1.99)  >  0.05  - -
White 1  153/299  1.21  (0.91-1.61)  >  0.05  - -
Latin America  1  157/237  0.88  (0.57-1.36)  >  0.05  - -
Total 5  637/918  0.96  (0.79-1.16)  0.65  56.1  0.06
CI, conﬁdence interval; SLCO1B1, solute carrier organic anion transporter family member 1B1.
Table  6  Genotypic  frequencies  of  SLCO1B1  463  C>A  in  neonatal  hyperbilirubinemic  cases  and  in  controls.
Study  Country  of  origin  Cases  (n)  Controls  (n)
C/C  C/A  A/A  C/C  C/A  A/A
Huang  et  al.15 Taiwan  42  0  0  73  0  0
Prachukthum  et  al.17 Thailand  91  0  0  86  0  0
Watchko  et  al.18 America  122  30  1  223  65  9
SLCO1B1, solute carrier organic anion transporter family member 1B1.
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f  153  (20.26%)  neonates  in  the  hyperbilirubinemic  group
one homozygous  and  30  heterozygous)  compared  to  74  of
99 (24.75%)  in  the  control  groups  (nine  homozygous  and
5 heterozygous).  In  that  study18 there  were  no  statistically
igniﬁcant differences  in  the  risk  of  neonatal  hyperbiliru-
inemia between  SLCO1B1  463  C>A  allele  carriers  (A/A+C/A)
nd C/C  allele  carriers  (OR,  0.77;  95%  CI:  0.48--1.23);  the
ame was  observed  when  comparing  the  A  allele  to  the  C
llele in  the  SLCO1B1  463  C>A  mutation  (OR,  0.72;  95%  CI:
.47--1.11).
iscussion
he  present  systematic  review  with  meta-analysis  indi-
ated that  there  was  no  statistically  signiﬁcant  difference
n the  risk  of  neonatal  hyperbilirubinemia  in  those  with  the
LCO1B1 388  G>A  mutation.  In  subgroup  analyses  based  on
thnicity, no  signiﬁcant  associations  were  found  in  white,
sian, Thai,  Brazilian,  and  Malaysian  populations,  but  sig-
iﬁcant associations  were  present  in  Chinese  neonates.
eta-analysis of  ﬁve  case-control  studies  indicated  that
here was  no  statistically  signiﬁcant  difference  in  the  risk  of
eonatal hyperbilirubinemia  for  those  with  the  SLCO1B1  521
>C  mutation.  In  subgroup  analyses  based  on  ethnicity,  no
igniﬁcant associations  were  found  in  white,  Asian,  Brazil-
an, and  Malaysian  populations,  but  a  low  risk  was  found
n Chinese  neonates.  Three  case-control  studies  from  three
ountries assessed  the  association  between  the  SLCO1B1  463
>A  mutation  and  neonatal  hyperbilirubinemia.  No  carriage
f the  C  to  A  substitution  at  nucleotide  463  was  detected
mong three  studies,  and  only  one  study  of  American  infants
eported the  variant  SLCO1B1  at  nt  463  in  hyperbilirubinemic
nd in  control  infants  (0.156  and  0.155,  respectively),  with
o statistically  signiﬁcant  difference  between  the  groups.
Egger’s  test  provided  no  evidence  for  funnel  plot  asym-
etry in  the  comparison  of  the  SLCO1B1  388  G>A  and  521
>C mutations  and  neonatal  hyperbilirubinemia.  Three  stud-
es focused  on  the  relationship  between  the  SLCO1B1  463
>A mutation  and  neonatal  hyperbilirubinemia:  two  stud-
es did  not  detect  a  carriage  of  the  C  to  A  substitution,  and
ne study  showed  a  non-signiﬁcant  increase  in  the  risk  of
eonatal hyperbilirubinemia.  No  signiﬁcant  inter-study  het-
rogeneity  was  observed  in  the  analyses.  Therefore,  it  is
elieved that  the  results  of  the  present  meta-analysis  are
eliable.
In the  nine  included  studies,  which  analyzed  the  associ-
tion between  the  SLCO1B1  388  G>A  mutation  and  neonatal
yperbilirubinemia, only  three  studies  from  China  showed
 positive  relationship.13--15 In  ﬁve  included  studies  that
nalyzed the  association  between  the  SLCO1B1  521  T>C
utation and  neonatal  hyperbilirubinemia,  only  one  study
rom China  showed  a  negative  relationship.12 In  other  popu-
ations, no  statistically  signiﬁcant  difference  was  observed.
he genetics  of  racial  differences  might  explain  the  vari-
bility in  prevalence  of  neonatal  hyperbilirubinemia  among
ifferent ethnic  groups.
An  in  vitro  expression  study  demonstrated  that  SLCO1B1
88 G>A  variations  are  consistently  associated  with
educed transport  activity  of  SLCO1B1.21 Evidence  sug-
ests that  transient  hyperbilirubinemia  may  be  caused  by
otent SLCO1B1  inhibitors,  such  as  indinavir,  saquinavir,Liu  J  et  al.
yclosporine  A,  and  rifamycin.22 Following  rifampicin  admin-
stration (450  mg/day)  for  ﬁve  consecutive  days,  serum
ilirubin levels  were  signiﬁcantly  increased,  and  unconju-
ated bilirubin,  direct  bilirubin,  and  total  bilirubin  levels
ere increased  by  24.9%,  31.5%,  and  26.8%,  respectively.23
hus,  modulation  of  the  transporting  activity  of  SLCO1B1
ould alter  the  transportation  and  subsequent  elimination  of
erum bilirubin.  The  SLCO1B1*1B  (C388  G--C521T)  haplotype
as been  associated  with  increased  OATP1B1  transport  activ-
ty in  vitro  in  studies  performed  with  bromosulfophthalein
nd estrone-3-sulfate.21,24 SLCO1B1  may  be  a  useful  ther-
peutic target  for  neonatal  hyperbilirubinemia,  but  further
tudies are  needed  to  explore  this  hypothesis,  and  to  conﬁrm
hether some  SLCO1B1  activators  could  improve  the  trans-
orting activity  of  the  SLCO1B1  gene,  which  could  enhance
ptake of  bilirubin  from  blood  to  bile  and  decrease  serum
ilirubin levels.
In  addition,  there  were  also  some  limitations  in  this
tudy. Firstly,  the  diagnostic  criteria  for  neonatal  hyper-
ilirubinemia were  not  consistent.  Secondly,  there  were
tudies included  with  a  relatively  small  population  of  sub-
ects, which  might  have  some  effect  on  the  power  of
ur analysis.  Thirdly,  various  other  factors  may  also  have
ontributed to  neonatal  hyperbilirubinemia,  such  as  envi-
onmental factors,  which  were  not  explained  in  the  included
tudies.
onclusion
he  present  systematic  review  with  meta-analysis  shows
hat the  388  G>A  mutation  of  the  SLCO1B1  gene  is  a  risk
actor for  developing  neonatal  hyperbilirubinemia  in  Chi-
ese neonates,  but  not  in  white,  Thai,  Brazilian,  or  Malaysian
opulations; the  SLCO1B1  521  T>C  mutation  provides  protec-
ion for  neonatal  hyperbilirubinemia  in  Chinese  neonates,
ut not  in  white,  Thai,  Brazilian  or  Malaysian  neonates.
ince other  factors  involved  in  neonatal  hyperbilirubinemia
ight impact  on  the  association,  further  study  is  needed  to
ssess the  effects  of  genetic  variations  after  adjusting  for
he effect  of  other  factors.
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